A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States
The purpose of this study is to understand real-world effectiveness of luspatercept treatment among erythropoiesis-stimulating agents -naïve patients with lower-risk- myelodysplastic syndromes in the United States
Myelodysplastic Syndromes
DRUG: Luspatercept|DRUG: Erythropoiesis-stimulating agents
Participant baseline demographics, Baseline|Participant baseline clinical characteristics, Baseline|Time from Lower Risk- myelodysplastic syndromes diagnosis to index treatment initiation, Baseline|Rationale for therapy selection, Baseline|Duration of index treatment, Up to 15 months|Treatment dose at treatment initiation and discontinuation, Up to 6 months|Treatment dose/dosing schedule changes, and treatment interruptions, Up to 12 months|Other supportive care therapies prescribed while on index treatment, Up to 15 months|Treatments prescribed post index treatment, Up to 15 months|Treatments for anemia management received after discontinuing the index treatment, Up to 15 months|Receipt of stem cell transplant at any time post index treatment, Up to 15 months|Participant red-blood cell (RBC) transfusion burden post index treatment, At 3-months, and up to 6 months|Hematologic improvement-erythroid (HI-E) response post index treatment, At 3-months, and up to 6 months|Progression to acute myeloid leukemia post index treatment, Up to 15 months|Progression to high-risk myelodysplastic syndromes per the International Prognostic Scoring System (IPSS) or its revised version (IPSS-R) criteria, Up to 15 months|Participant adverse events during and post index treatment, Up to 15 months|Overall survival (OS), At 3-, 6-, 12-, and up to 15-months|Healthcare resource utilization (HCRU) during index treatment, Up to 15 months
The purpose of this study is to understand real-world effectiveness of luspatercept treatment among erythropoiesis-stimulating agents -naïve patients with lower-risk- myelodysplastic syndromes in the United States